For clinical application in humans, after first confirming that antibodies capable of inhibiting sEH can be raised in human blood, patients with overlapping risks of atherosclerosis, such as those who are prone to myocardial infarction due to diabetes, hypertension, and/or obesity, may be eligible for the sEH vaccine. This evidence concerns the gene EPHX2 and diabetes mellitus.